当前位置: 首页 >> 检索结果
241. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
作者: Zsa Zsa R M Weerts.;Ad A M Masclee.;Ben J M Witteman.;Cees H M Clemens.;Bjorn Winkens.;Jacobus R B J Brouwers.;Henderik W Frijlink.;Jean W M Muris.;Niek J De Wit.;Brigitte A B Essers.;Jan Tack.;Johanna T W Snijkers.;Andrea M H Bours.;Annieke S de Ruiter-van der Ploeg.;Daisy M A E Jonkers.;Daniel Keszthelyi.
来源: Gastroenterology. 2020年158卷1期123-136页
Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small-intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil.
242. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
作者: William J Sandborn.;Filip Baert.;Silvio Danese.;Željko Krznarić.;Taku Kobayashi.;Xiaopan Yao.;Jingjing Chen.;Maria Rosario.;Siddharth Bhatia.;Krisztina Kisfalvi.;Geert D'Haens.;Séverine Vermeire.
来源: Gastroenterology. 2020年158卷3期562-572.e12页
Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer a subcutaneous formulation of vedolizumab for maintenance treatment. Subcutaneous vedolizumab was investigated as maintenance treatment in patients with moderately to severely active ulcerative colitis.
243. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
作者: Anna S Lok.;Mark S Sulkowski.;Jens J Kort.;Ira Willner.;K Rajender Reddy.;Mitchell L Shiffman.;Mohamed A Hassan.;Brian L Pearlman.;Federico Hinestrosa.;Ira M Jacobson.;Giuseppe Morelli.;Joy A Peter.;Monika Vainorius.;Larry C Michael.;Michael W Fried.;Gary P Wang.;Wenjing Lu.;Lois Larsen.;David R Nelson.
来源: Gastroenterology. 2019年157卷6期1506-1517.e1页
Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without ribavirin, in patients with HCV genotype 1 infection with treatment failure after sofosbuvir and an NS5A inhibitor.
244. Clip Closure After Resection of Large Colorectal Lesions With Substantial Risk of Bleeding.
作者: Eduardo Albéniz.;Marco Antonio Álvarez.;Jorge C Espinós.;Oscar Nogales.;Carlos Guarner.;Pedro Alonso.;Manuel Rodríguez-Téllez.;Alberto Herreros de Tejada.;José Santiago.;Marco Bustamante-Balén.;Joaquín Rodríguez Sánchez.;Felipe Ramos-Zabala.;Eduardo Valdivielso.;Felipe Martínez-Alcalá.;María Fraile.;Alfonso Elosua.;María Fernanda Guerra Veloz.;Berta Ibáñez Beroiz.;Ferrán Capdevila.;Mónica Enguita-Germán.
来源: Gastroenterology. 2019年157卷5期1213-1221.e4页
It is not clear whether closure of mucosal defects with clips after colonic endoscopic mucosal resection (EMR) prevents delayed bleeding, although it seems to have no protective effects when risk is low. We performed a randomized trial to evaluate the efficacy of complete clip closure of large (≥2 cm) nonpedunculated colorectal lesions after EMR in patients with an estimated average or high risk of delayed bleeding.
245. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial.
作者: Saeede Saadati.;Amir Sadeghi.;Asieh Mansour.;Zahra Yari.;Hossein Poustchi.;Mehdi Hedayati.;Behzad Hatami.;Azita Hekmatdoost.
来源: BMC Gastroenterol. 2019年19卷1期133页
The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).
246. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer.
作者: Liyana Zaharuddin.;Norfilza Mohd Mokhtar.;Khairul Najmi Muhammad Nawawi.;Raja Affendi Raja Ali.
来源: BMC Gastroenterol. 2019年19卷1期131页
Our study aimed to determine the effect of probiotic consumption containing six viable microorganisms of 30 × 1010 cfu Lactobacillus and Bifidobacteria strains for six months on clinical outcomes and inflammatory cytokines (TNF-α, IFN-γ, IL-6, IL-10, IL-12, IL-17A, IL-17C and IL-22) in patients with colorectal cancer.
247. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
作者: Katherine Li.;Joshua R Friedman.;Daphne Chan.;Paul Pollack.;Feifei Yang.;Douglas Jacobstein.;Carrie Brodmerkel.;Christopher Gasink.;Brian G Feagan.;William J Sandborn.;Paul Rutgeerts.;Gert De Hertogh.
来源: Gastroenterology. 2019年157卷4期1019-1031.e7页
Although ustekinumab is an effective therapy for moderate to severe Crohn's disease (CD), its effects on the microscopic manifestations of CD are unknown.
248. Fecal microbiota transplantation for ulcerative colitis: a prospective clinical study.
作者: Yan Tian.;Yan Zhou.;Sisi Huang.;Jun Li.;Kui Zhao.;Xiaohui Li.;Xiangchen Wen.;Xiao-An Li.
来源: BMC Gastroenterol. 2019年19卷1期116页
Fecal microbiota transplantation may contribute to disease remission in ulcerative colitis; however, the factors that determine the effects of treatment remain unknown. The aim of the present study was to prospectively investigate the clinical efficacy of fecal microbiota transplantation in patients with ulcerative colitis and identify the bacterial signatures associated with clinical remission.
249. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
作者: Amit Assa.;Manar Matar.;Dan Turner.;Efrat Broide.;Batia Weiss.;Oren Ledder.;Anat Guz-Mark.;Firas Rinawi.;Shlomi Cohen.;Chani Topf-Olivestone.;Ron Shaoul.;Baruch Yerushalmi.;Raanan Shamir.
来源: Gastroenterology. 2019年157卷4期985-996.e2页
Proactive monitoring of drug trough concentrations and antibodies against drugs might help determine whether patients are likely to respond to treatment and increase efficacy. We investigated whether proactive drug monitoring is associated with higher rates of clinical remission in pediatric patients with Crohn's disease (CD).
250. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.
作者: Arie Levine.;Eytan Wine.;Amit Assa.;Rotem Sigall Boneh.;Ron Shaoul.;Michal Kori.;Shlomi Cohen.;Sarit Peleg.;Hussein Shamaly.;Avi On.;Peri Millman.;Lee Abramas.;Tomer Ziv-Baran.;Shannan Grant.;Guila Abitbol.;Katherine A Dunn.;Joseph P Bielawski.;Johan Van Limbergen.
来源: Gastroenterology. 2019年157卷2期440-450.e8页
Exclusive enteral nutrition (EEN) is recommended for children with mild to moderate Crohn's disease (CD), but implementation is challenging. We compared EEN with the CD exclusion diet (CDED), a whole-food diet coupled with partial enteral nutrition (PEN), designed to reduce exposure to dietary components that have adverse effects on the microbiome and intestinal barrier.
251. Efficacy of Prophylactic Hemoclips in Prevention of Delayed Post-Polypectomy Bleeding in Patients With Large Colonic Polyps.
作者: Linda A Feagins.;Andrew D Smith.;Daniel Kim.;Akeel Halai.;Suneetha Duttala.;Benjamin Chebaa.;Tisha Lunsford.;John Vizuete.;Miriam Mara.;Ranjan Mascarenhas.;Rabia Meghani.;Leon Kundrotas.;Kerry B Dunbar.;Daisha J Cipher.;William V Harford.;Stuart J Spechler.
来源: Gastroenterology. 2019年157卷4期967-976.e1页
The efficacy of prophylactic placement of hemoclips to prevent delayed bleeding after removal of large colonic polyps has not been established. We conducted a randomized equivalence study to determine whether prophylactic placement of hemoclips affects incidence of delayed post-polypectomy bleeding (PPB).
252. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
作者: Paul Moayyedi.;John W Eikelboom.;Jackie Bosch.;Stuart J Connolly.;Leanne Dyal.;Olga Shestakovska.;Darryl Leong.;Sonia S Anand.;Stefan Störk.;Kelley R H Branch.;Deepak L Bhatt.;Peter B Verhamme.;Martin O'Donnell.;Aldo P Maggioni.;Eva M Lonn.;Leopoldo S Piegas.;Georg Ertl.;Matyas Keltai.;Nancy Cook Bruns.;Eva Muehlhofer.;Gilles R Dagenais.;Jae-Hyung Kim.;Masatsugu Hori.;P Gabriel Steg.;Robert G Hart.;Rafael Diaz.;Marco Alings.;Petr Widimsky.;Alvaro Avezum.;Jeffrey Probstfield.;Jun Zhu.;Yan Liang.;Patricio Lopez-Jaramillo.;Ajay K Kakkar.;Alexander N Parkhomenko.;Lars Ryden.;Nana Pogosova.;Antonio L Dans.;Fernando Lanas.;Patrick J Commerford.;Christian Torp-Pedersen.;Tomek J Guzik.;Dragos Vinereanu.;Andrew M Tonkin.;Basil S Lewis.;Camilo Felix.;Khalid Yusoff.;Kaj P Metsarinne.;Keith A A Fox.;Salim Yusuf.; .
来源: Gastroenterology. 2019年157卷3期682-691.e2页
Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.
253. Novel 1 L polyethylene glycol-based bowel preparation (NER1006): proof of concept assessment versus standard 2 L polyethylene glycol with ascorbate - a randomized, parallel group, phase 2, colonoscopist-blinded trial.
作者: Lucy B Clayton.;Bola Tayo.;Marc Halphen.;Rüdiger Kornberger.
来源: BMC Gastroenterol. 2019年19卷1期79页
Colonoscopy requires colon cleansing. For this, many polyethylene glycol (PEG)-based preparations still require a high preparation-volume intake. Using an increased osmotic load with ascorbate (Asc), five new low-volume PEG-based bowel preparations (LVPEG) were tested for clinical proof of concept.
255. Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers.
作者: Brynjulf Mortensen.;Clodagh Murphy.;John O'Grady.;Mary Lucey.;Gafer Elsafi.;Lillian Barry.;Vibeke Westphal.;Anja Wellejus.;Oksana Lukjancenko.;Aron C Eklund.;Henrik Bjørn Nielsen.;Adam Baker.;Anders Damholt.;Johan E T van Hylckama Vlieg.;Fergus Shanahan.;Martin Buckley.
来源: Gastroenterology. 2019年157卷3期637-646.e4页
Enteropathy and small-intestinal ulcers are common adverse effects of nonsteroidal anti-inflammatory drugs such as acetylsalicylic acid (ASA). Safe, cytoprotective strategies are needed to reduce this risk. Specific bifidobacteria might have cytoprotective activities, but little is known about these effects in humans. We used serial video capsule endoscopy (VCE) to assess the efficacy of a specific Bifidobacterium strain in healthy volunteers exposed to ASA.
256. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
作者: Paul Moayyedi.;John W Eikelboom.;Jackie Bosch.;Stuart J Connolly.;Leanne Dyal.;Olga Shestakovska.;Darryl Leong.;Sonia S Anand.;Stefan Störk.;Kelly R H Branch.;Deepak L Bhatt.;Peter B Verhamme.;Martin O'Donnell.;Aldo P Maggioni.;Eva M Lonn.;Leopoldo S Piegas.;Georg Ertl.;Matyas Keltai.;Nancy Cook Bruns.;Eva Muehlhofer.;Gilles R Dagenais.;Jae-Hyung Kim.;Masatsugu Hori.;P Gabriel Steg.;Robert G Hart.;Rafael Diaz.;Marco Alings.;Petr Widimsky.;Alvaro Avezum.;Jeffrey Probstfield.;Jun Zhu.;Yan Liang.;Patricio Lopez-Jaramillo.;Ajay Kakkar.;Alexander N Parkhomenko.;Lars Ryden.;Nana Pogosova.;Antonio Dans.;Fernando Lanas.;Patrick J Commerford.;Christian Torp-Pedersen.;Tomek Guzik.;Dragos Vinereanu.;Andrew M Tonkin.;Basil S Lewis.;Camilo Felix.;Khalid Yusoff.;Kaj Metsarinne.;Keith A A Fox.;Salim Yusuf.; .
来源: Gastroenterology. 2019年157卷2期403-412.e5页
Antiplatelets and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk.
257. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
作者: Jian Sun.;Huiguo Ding.;Guofeng Chen.;Guiqiang Wang.;Lai Wei.;Jiming Zhang.;Qing Xie.;Mobin Wan.;Hong Tang.;Shijun Chen.;Zhiliang Gao.;Yuming Wang.;Dazhi Zhang.;Wenxiang Huang.;Jifang Sheng.;Qin Ning.;Dongliang Yang.;Jian Lu.;Chen Pan.;Yuxiu Yang.;Jue Wang.;Chuanzhen Sun.;Qixin Wang.;Jinlin Hou.
来源: BMC Gastroenterol. 2019年19卷1期65页
Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial.
258. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
作者: Rene M M van Aerts.;Wietske Kievit.;Hedwig M A D'Agnolo.;Charles J Blijdorp.;Niek F Casteleijn.;Shosha E I Dekker.;Johan W de Fijter.;Maatje van Gastel.;Tom J Gevers.;Liyanne F M van de Laarschot.;Marten A Lantinga.;Monique Losekoot.;Esther Meijer.;A Lianne Messchendorp.;Myrte K Neijenhuis.;Michelle J Pena.;Dorien J M Peters.;Mahdi Salih.;Darius Soonawala.;Edwin M Spithoven.;Folkert W Visser.;Jack F Wetzels.;Robert Zietse.;Ron T Gansevoort.;Joost P H Drenth.; .
来源: Gastroenterology. 2019年157卷2期481-491.e7页
Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues. We made use of data from an open-label, randomized trial to determine the effects of lanreotide on height-adjusted liver volume (hTLV) and combined height-adjusted liver and kidney volume (hTLKV) in patients with ADPKD.
259. Comparison of Underwater vs Conventional Endoscopic Mucosal Resection of Intermediate-Size Colorectal Polyps.
作者: Takeshi Yamashina.;Noriya Uedo.;Tomofumi Akasaka.;Taro Iwatsubo.;Yasuki Nakatani.;Takuji Akamatsu.;Takuji Kawamura.;Yoji Takeuchi.;Shigehiko Fujii.;Toshihiro Kusaka.;Toshio Shimokawa.
来源: Gastroenterology. 2019年157卷2期451-461.e2页
Endoscopic mucosal resection (EMR) with submucosal injection is an established method for removing colorectal polyps, although the en bloc resection rate decreases when polyp size exceeds 10 mm. Piecemeal resection increases local recurrence. Underwater EMR (UEMR) is an effective technique for removal of sessile colorectal polyps and we investigated whether it is superior to conventional EMR (CEMR).
260. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
作者: Carolina Boni.;Harry L A Janssen.;Marzia Rossi.;Seung Kew Yoon.;Andrea Vecchi.;Valeria Barili.;Eric M Yoshida.;Huy Trinh.;Timothy C Rodell.;Diletta Laccabue.;Arianna Alfieri.;Federica Brillo.;Paola Fisicaro.;Greta Acerbi.;Giuseppe Pedrazzi.;Pietro Andreone.;Carmela Cursaro.;Marzia Margotti.;Rosanna Santoro.;Valeria Piazzolla.;Maurizia R Brunetto.;Barbara Coco.;Daniela Cavallone.;Yang Zhao.;Adarsh Joshi.;Jacky Woo.;Audrey H Lau.;Anuj Gaggar.;G Mani Subramanian.;Benedetta Massetto.;Scott Fung.;Sang Hoon Ahn.;Xiaoli Ma.;Alessandra Mangia.;Carlo Ferrari.
来源: Gastroenterology. 2019年157卷1期227-241.e7页
One strategy to treat chronic hepatitis B virus (HBV) infection could be to increase the functions of virus-specific T cells. We performed a multicenter phase 2 study to evaluate the safety and efficacy of GS-4774, a yeast-based therapeutic vaccine engineered to express HBV antigens, given with tenofovir disoproxil fumarate (TDF) to untreated patients with chronic HBV infection.
|